The top ten pharmaceutical companies based on global vaccine revenue
market share in 2017 and a projection for 2024 include companies like CSL Behring.
In 2017, GlaxoSmithKline (GSK) was the top pharmaceutical company and held about 24 percent of the global vaccine market by revenue. GSK is expected to maintain their position as the top company and even gain a small amount of the market until 2024. Pfizer is expected to account for some 16 percent of the global vaccine market by 2024, largely due to success with its pneumococcal vaccine, Prevnar 13. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.
Seqirus/CSL Behring is among the global leaders and has provided patient consumers new vaccines with these recent approvals: AUDENZ the first and only adjuvanted, cell-based pandemic vaccine to provide active immunization against the influenza A virus H5N1 strain; FLUAD a seasonal vaccine in February 2020 in the US; and FLUCELVAX a seasonal vaccine for children and adults in Canada.
[READ MORE]
In 2017, GlaxoSmithKline (GSK) was the top pharmaceutical company and held about 24 percent of the global vaccine market by revenue. GSK is expected to maintain their position as the top company and even gain a small amount of the market until 2024. Pfizer is expected to account for some 16 percent of the global vaccine market by 2024, largely due to success with its pneumococcal vaccine, Prevnar 13. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.
Seqirus/CSL Behring is among the global leaders and has provided patient consumers new vaccines with these recent approvals: AUDENZ the first and only adjuvanted, cell-based pandemic vaccine to provide active immunization against the influenza A virus H5N1 strain; FLUAD a seasonal vaccine in February 2020 in the US; and FLUCELVAX a seasonal vaccine for children and adults in Canada.
[READ MORE]
